Cantourage Reports Strong Growth in Q1 2025

In the first quarter of 2025, Cantourage Group SE, a leading European medical cannabis company, showcased significant growth and profitability. The company's EBITDA margin ranged between 11 and 13%, highlighting its ability to combine expansion with efficient operations.

Cantourage's revenue exceeded EUR 25 million in Q1, with figures reaching over EUR 36 million by the end of April 2025. This illustrates Cantourage's robust growth trajectory, supported by a stable cost foundation and scalable operations.

CEO Philip Schetter emphasized the company’s focus on sustainable growth, achieved through international presence, reliable supply chains, and stringent quality standards. These elements differentiate Cantourage in the competitive market.